Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology.


Journal

Journal of managed care & specialty pharmacy
ISSN: 2376-1032
Titre abrégé: J Manag Care Spec Pharm
Pays: United States
ID NLM: 101644425

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 27 8 2021
Statut: ppublish

Résumé

The complement system is part of the innate immune response system, which comprises more than 50 distinct plasma and serum proteins that interact to opsonize pathogens (i.e., mark pathogens for destruction) and induce inflammatory responses to fight infection. The role of the complement system is 2-fold: immune surveillance and host defense. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, acquired, hematologic disease caused by somatic mutations in the gene PIGA in the hematopoietic stem cells. These stem cells produce abnormal clone blood cells that lack the complement regulatory proteins CD55 and CD59, causing the body to recognize these otherwise healthy red blood cells as damaged. The complement system destroys cells without these protective proteins, resulting in general hemolysis. PNH is characterized by fatigue; hemolytic anemia that can be severe and debilitating; increased lactic dehydrogenase level, reticulocyte count, and bilirubin level; propensity for thrombotic events; and renal dysfunction. Epidemiologic data, while sparse, suggest that an estimated 5,000-6,000 individuals in the United States are affected by PNH. If left untreated, PNH has a 10-year mortality rate of 29%, although the natural history of this disease has been recently altered by the introduction of complement inhibitors for the treatment of PNH.

Identifiants

pubmed: 33356782
doi: 10.18553/jmcp.2020.26.12-b.s3
pmc: PMC10408413
doi:

Substances chimiques

Complement System Proteins 9007-36-7

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S3-S8

Références

Blood. 2005 Dec 1;106(12):3699-709
pubmed: 16051736
Semin Hematol. 2009 Jan;46(1 Suppl 1):S1-S16
pubmed: 19171207
Nat Rev Nephrol. 2018 Jan;14(1):26-47
pubmed: 29199277
Haematologica. 2018 Jan;103(1):9-17
pubmed: 29246924
Am J Blood Res. 2011;1(2):160-6
pubmed: 22432077
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):208-216
pubmed: 27913482
Cytometry B Clin Cytom. 2010 Jul;78(4):211-30
pubmed: 20533382
Blood. 2008 Oct 15;112(8):3099-106
pubmed: 18535202
Ann Hematol. 2020 Jul;99(7):1505-1514
pubmed: 32390114
Blood. 2014 Oct 30;124(18):2804-11
pubmed: 25237200
Blood Rev. 2008 Mar;22(2):65-74
pubmed: 18063459
J Clin Lab Anal. 2020 Jan;34(1):e23008
pubmed: 31502726
Haematologica. 2005 Dec;90(12 Suppl):ECR40
pubmed: 16464755
Hematology. 2018 Sep;23(8):558-566
pubmed: 29486674
Nat Rev Dis Primers. 2017 May 18;3:17028
pubmed: 28516949
Ther Adv Hematol. 2019 Sep 09;10:2040620719873321
pubmed: 31523413
Hematology. 2015 Jun;20(5):263-6
pubmed: 25148373
Oncology. 2005;69 Suppl 2:2-7
pubmed: 16244504
Medicine (Baltimore). 2004 May;83(3):193-207
pubmed: 15118546
Dis Markers. 2015;2015:635670
pubmed: 26819490
Cell Res. 2010 Jan;20(1):34-50
pubmed: 20010915
PLoS Comput Biol. 2018 Jun 18;14(6):e1006133
pubmed: 29912864
Int J Hematol. 2018 Jun;107(6):656-665
pubmed: 29383624
Blood. 1993 Aug 15;82(4):1192-6
pubmed: 7688991
Intern Med J. 2016 Sep;46(9):1044-53
pubmed: 27305361

Auteurs

Meryem Bektas (M)

Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle, NC.

Catherine Copley-Merriman (C)

Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle, NC.

Shahnaz Khan (S)

Market Access and Outcomes Strategy, RTI Health Solutions, Research Triangle, NC.

Sujata P Sarda (SP)

Global Health Economics and Outcomes Research, Apellis Pharmaceuticals, Waltham, MA.

Jamile M Shammo (JM)

Department of Internal Medicine, Rush University Medical Center, Chicago, IL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH